[go: up one dir, main page]

IT1256110B - Procedimento di coniugazione di nucleosidi antivirali con albumina umana lattosaminata - Google Patents

Procedimento di coniugazione di nucleosidi antivirali con albumina umana lattosaminata

Info

Publication number
IT1256110B
IT1256110B ITMI922673A ITMI922673A IT1256110B IT 1256110 B IT1256110 B IT 1256110B IT MI922673 A ITMI922673 A IT MI922673A IT MI922673 A ITMI922673 A IT MI922673A IT 1256110 B IT1256110 B IT 1256110B
Authority
IT
Italy
Prior art keywords
human albumin
conjugation procedure
antiviral nucleosides
lactosaminated human
lactosaminated
Prior art date
Application number
ITMI922673A
Other languages
English (en)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of ITMI922673A0 publication Critical patent/ITMI922673A0/it
Priority to ITMI922673A priority Critical patent/IT1256110B/it
Priority to EP94901834A priority patent/EP0624098B1/en
Priority to US08/256,415 priority patent/US5594110A/en
Priority to DE69328082T priority patent/DE69328082T2/de
Priority to PT94901834T priority patent/PT624098E/pt
Priority to AT94901834T priority patent/ATE190504T1/de
Priority to PCT/EP1993/003261 priority patent/WO1994012218A1/en
Priority to AU56262/94A priority patent/AU5626294A/en
Priority to ES94901834T priority patent/ES2144046T3/es
Priority to DK94901834T priority patent/DK0624098T3/da
Publication of ITMI922673A1 publication Critical patent/ITMI922673A1/it
Application granted granted Critical
Publication of IT1256110B publication Critical patent/IT1256110B/it
Priority to GR20000401297T priority patent/GR3033611T3/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Effettuando la reazione di coniugazione tra un nucleoside antivirale fosforilato, in particolare adenina arabinoside monofosfato, in forma di imidazolide con albumina umana lattosaminata a pH superiore a 7,5 si ottengono nel coniugato risultante rapporti molari farmaco/L-HSA almeno uguali a quelli ottenuti usando ECDI senza i problemi ed inconvenienti collaterali presentati da questi ultimi. Di preferenza la reazione di coniugazione viene effettuata a temperatura di 37° C, ed a pH di 8,5-9,5.
ITMI922673A 1992-11-23 1992-11-23 Procedimento di coniugazione di nucleosidi antivirali con albumina umana lattosaminata IT1256110B (it)

Priority Applications (11)

Application Number Priority Date Filing Date Title
ITMI922673A IT1256110B (it) 1992-11-23 1992-11-23 Procedimento di coniugazione di nucleosidi antivirali con albumina umana lattosaminata
PCT/EP1993/003261 WO1994012218A1 (en) 1992-11-23 1993-11-20 Process of conjugation of antiviral nucleosides with lactosaminated human albumin
US08/256,415 US5594110A (en) 1992-11-23 1993-11-20 Process of conjugation of antiviral nucleosides with lactosaminated human albumin
DE69328082T DE69328082T2 (de) 1992-11-23 1993-11-20 Konjugation von antivirale Nukleosiden mit Lactosaminaten-Human-Albumin
PT94901834T PT624098E (pt) 1992-11-23 1993-11-20 Processo de conjugacao de nucleosidos antivirais com albumina humana lactosaminada
AT94901834T ATE190504T1 (de) 1992-11-23 1993-11-20 Konjugation von antivirale nukleosiden mit lactosaminaten-human-albumin
EP94901834A EP0624098B1 (en) 1992-11-23 1993-11-20 Process of conjugation of antiviral nucleosides with lactosaminated human albumin
AU56262/94A AU5626294A (en) 1992-11-23 1993-11-20 Process of conjugation of antiviral nucleosides with lactosaminated human albumin
ES94901834T ES2144046T3 (es) 1992-11-23 1993-11-20 Procedimiento de conjugacion de nucleosidos antivirales con albumina humana lactosaminada.
DK94901834T DK0624098T3 (da) 1992-11-23 1993-11-20 Fremgangsmåde til konjugering af antivirale nukleosider med lactosamineret humant albumin
GR20000401297T GR3033611T3 (en) 1992-11-23 2000-06-07 Process of conjugation of antiviral nucleosides with lactosaminated human albumin.

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ITMI922673A IT1256110B (it) 1992-11-23 1992-11-23 Procedimento di coniugazione di nucleosidi antivirali con albumina umana lattosaminata

Publications (3)

Publication Number Publication Date
ITMI922673A0 ITMI922673A0 (it) 1992-11-23
ITMI922673A1 ITMI922673A1 (it) 1994-05-23
IT1256110B true IT1256110B (it) 1995-11-28

Family

ID=11364330

Family Applications (1)

Application Number Title Priority Date Filing Date
ITMI922673A IT1256110B (it) 1992-11-23 1992-11-23 Procedimento di coniugazione di nucleosidi antivirali con albumina umana lattosaminata

Country Status (11)

Country Link
US (1) US5594110A (it)
EP (1) EP0624098B1 (it)
AT (1) ATE190504T1 (it)
AU (1) AU5626294A (it)
DE (1) DE69328082T2 (it)
DK (1) DK0624098T3 (it)
ES (1) ES2144046T3 (it)
GR (1) GR3033611T3 (it)
IT (1) IT1256110B (it)
PT (1) PT624098E (it)
WO (1) WO1994012218A1 (it)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5632915A (en) * 1994-08-29 1997-05-27 Gerber Garment Technology, Inc. Laser material processing apparatus and a work table therefor
US5693791A (en) * 1995-04-11 1997-12-02 Truett; William L. Antibiotics and process for preparation
US20020099013A1 (en) * 2000-11-14 2002-07-25 Thomas Piccariello Active agent delivery systems and methods for protecting and administering active agents
US8394813B2 (en) 2000-11-14 2013-03-12 Shire Llc Active agent delivery systems and methods for protecting and administering active agents
ITMI20010027A1 (it) * 2001-01-10 2002-07-10 Uni Di Bologna Dipartimento Di Composizioni teraputiche per una chemioterapia locoregionale non invasiva delle micrometastasi epatiche
US7169752B2 (en) * 2003-09-30 2007-01-30 New River Pharmaceuticals Inc. Compounds and compositions for prevention of overdose of oxycodone
US20060014697A1 (en) * 2001-08-22 2006-01-19 Travis Mickle Pharmaceutical compositions for prevention of overdose or abuse
CA2663083A1 (en) 2006-09-08 2008-03-13 Ambrx, Inc. Modified human plasma polypeptide or fc scaffolds and their uses
ES2764100T3 (es) * 2009-04-15 2020-06-02 Abraxis Bioscience Llc Composiciones de nanopartículas exentas de priones y métodos
US9534243B2 (en) 2013-02-07 2017-01-03 The United States Of America, As Represented By The Secretary Of Commerce Nucleotide analogs and process for making same enzyme

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1177381B (it) * 1984-12-11 1987-08-26 Baldacci Lab Spa Metodo per la preparazione di coniugati della adenina-9-beta-d-arabino furano-side 5' monofosfato con albumina umana lattosaminata, coniugati risultanti e relative composizioi terapeuticamente attive
IT1207507B (it) * 1985-10-21 1989-05-25 Baldacci Lab Spa Coniugato della 9-(2-idrossietossimetil)guanina con albumina umana lattosaminata, procedimento per la sua preparazione e composizioni farmaceutiche che la contengono.

Also Published As

Publication number Publication date
PT624098E (pt) 2000-08-31
ES2144046T3 (es) 2000-06-01
ATE190504T1 (de) 2000-04-15
ITMI922673A0 (it) 1992-11-23
DK0624098T3 (da) 2000-06-05
EP0624098A1 (en) 1994-11-17
US5594110A (en) 1997-01-14
ITMI922673A1 (it) 1994-05-23
AU5626294A (en) 1994-06-22
EP0624098B1 (en) 2000-03-15
DE69328082T2 (de) 2000-08-24
GR3033611T3 (en) 2000-10-31
DE69328082D1 (de) 2000-04-20
WO1994012218A1 (en) 1994-06-09

Similar Documents

Publication Publication Date Title
NO180541C (no) Analogifremgangsmåte for fremstilling av terapeutisk aktive 9-purinylfosfonsyrederivater og mellomprodukt for fremstilling derav
IT1256110B (it) Procedimento di coniugazione di nucleosidi antivirali con albumina umana lattosaminata
MY102693A (en) Antiviral nucleosides
NO974077L (no) Fremgangsmåte for fremstilling av 2'-O-substituerte pyrimidiner og oligomeriske forbindelser derav
ATE116648T1 (de) Therapeutische nucleoside.
ATE254132T1 (de) Antivirale pyrimidin nucleoside derivate
SE8900192D0 (sv) Dideoxididehydrokarbocykliska nukleosider
PT747389E (pt) Derivados de nucleosido 3'-substituidos
IE46107L (en) Pyrimidine nucleosides
FI91763C (fi) Menetelmä terapeuttisesti käyttökelpoisen 2',3'-dideoksi-3'-fluoripyrimidiini- tai -puriininukleosidin valmistamiseksi
Cook et al. New class of potent guanine antimetabolites. Synthesis of 3-deazaguanine, 3-deazaguanosine, and 3-deazaguanylic acid by a novel ring closure of imidazole precursors
NO891835L (no) Prodrug-former av 2',3'-didehydro-2',3'-dideoksy-nukleosider.
DE69533856D1 (de) L-pyranosyl-nukleoside
ATE98249T1 (de) Phosphonoalkylpurin-derivate.
TR200002318T2 (tr) Nükleositler
NO974512L (no) Fremgangsmåte for syntese av nukleosid-analoger
YU78687A (sh) Postopek za pripravo derivatov purina
ATE77386T1 (de) Therapeutische nucleoside.

Legal Events

Date Code Title Description
0001 Granted
TA Fee payment date (situation as of event date), data collected since 19931001

Effective date: 19971127